Plasma alpha‐synuclein detected by single molecule array is increased in PD. Issue 3 (15th February 2019)

• Record Type: Journal Article
• Authors: Ng, Adeline S. L.; Tan, Yi Jayne; Lu, Zhonghao; Ng, Ebonne Y. L.; Ng, Samuel Y. E.; Chia, Nicole S. Y.; Setiawan, Fiona; Xu, Zheyu; Tay, Kay Yaw; Prakash, Kumar M.; Au, Wing Lok; Tan, Eng‐King; Tan, Louis C. S.
• Is Part Of: Annals of clinical and translational neurology. Volume 6:Issue 3(2019)
• Page Start: 615
• Page End: 619
• Publication Date: 2019-02-15
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.729
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha‐synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition (MMSE ≤ 25) than controls ( P = 0.016, Bonferroni corrected P = 0.047). Alpha‐synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.